Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1961MR)

This product GTTS-WQ1961MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1961MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11551MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ10485MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ2391MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ4554MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ1758MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ13830MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ9775MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ11692MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW